DOI: https://doi.org/10.22141/2224-0721.15.7.2019.186061

Pathogenesis of diabetic retinopathy: a literature review

M.L. Kyryliuk, V.A. Іshchenko

Abstract


The review presents data on the pathogenesis of diabetic retinopathy. The importance of increasing the activity of the polyol pathway of glucose metabolism, non-enzymatic glycation of proteins, activation of protein kinase C, carbonic anhydrase, hemodynamic changes and the activity of the renin-angiotensin system in the development of diabetes and its microvascular complications is indicated. Particular attention is paid to the role of oxidative stress, growth factors, as well as metabolic syndrome and obesity in the development and progression of diabetic retinopathy.

Keywords


diabetic retinopathy; pathogenesis; review

References


International Diabetes Association. IDF Diabetes Atlas. 7th ed. 2017. Available from: http://www.diabetesatlas.org/.

Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of Diabetic Retinopathy. ISRN Ophthalmol. 2013 Jan 15;2013:343560. doi: 10.1155/2013/343560.

Gardner TW, Davila JR. The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):1-6. doi: 10.1007/s00417-016-3548-y.

Lee R, Wong TY, Charumathi S. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17. doi: 10.1186/s40662-015-0026-2.

Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev. 2007 Feb;3(1):3-14. doi: 10.2174/157339907779802139.

Hattori T, Matsubara A, Taniguchi K, Ogura Y. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Curr Eye Res. 2010 Feb;35(2):146-54. doi: 10.3109/02713680903447918.

Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Current Medicinal Chemistry. 2006;13(27):3307-3317. doi: 10.2174/092986706778773086.

Wirostko T, Wong Y, Simó R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008 Nov;27(6):608-21. doi: 10.1016/j.preteyeres.2008.09.002.

Cui Y, Xu X, Bi H, et al. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res. 2006 Oct;83(4):807-16. doi: 10.1016/j.exer.2006.03.024.

Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Experimental Diabesity Research. 2007;2007. Exp Diabetes Res. 2007;2007:43603. doi: 10.1155/2007/43603.

Zhang XL, Wen L, Chen YJ, Zhu Y. Vascular endothelial growth factor up-regulates the expression of intracellular adhesion molecule-1 in retinal endothelial cells via reactive oxygen species, but not nitric oxide. Chin Med J (Engl). 2009 Feb 5;122(3):338-43.

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010 Jul 10;376(9735):124-36. doi: 10.1016/S0140-6736(09)62124-3.

Brownlee М. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. doi: 10.2337/diabetes.54.6.1615.

Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3832-41. doi: 10.1167/iovs.10-6368.

Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011 Aug;11(4):244-52. doi: 10.1007/s11892-011-0198-7.

Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci. 2006 Jun;27(6):317-23. DOI: 10.1016/j.tips.2006.04.003.

Min SH, Lee TI, Chung YS, Kim HK. Transforming growth factor-α levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006 Sep;20(3):162-5. doi: 10.3341/kjo.2006.20.3.162.

Eckardt U. Erythropoietin and microvascular diabetic complications. Nephrol Dial Transplant. 2009 Feb;24(2):388-90. doi: 10.1093/ndt/gfn590.

Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: Hopes and fears for a new therapeutic strategy. Diabetologia. 2008 Sep;51(9):1574-80. doi: 10.1007/s00125-008-0989-9.

Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol. 2004 Dec;15(6):508-18. doi: 10.1097/01.icu.0000143685.60479.3b.

Villarroel M, Ciudin A, Hernández C, Simó R. Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes. 2010 May 15;1(2):57-64. doi: 10.4239/wjd.v1.i2.57.

Yee P, Weymouth AE, Fletcher EL, Vingrys AJ. A Role for Omega-3 Polyunsaturated Fatty Acid Supplements in Diabetic Neuropathy. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1755-64. doi: 10.1167/iovs.09-3792.

Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005 Nov;29(11):1308-14. doi: 10.1038/sj.ijo.0802987.

Patel Sh, Sternberg P. Jr. Diabetic Retinopathy and Antivascular Endothelial Growth Factor Agents. JAMA Ophthalmol. 2017 Jun 1;135(6):568-569. doi: 10.1001/jamaophthalmol.2017.0318.

Wilkinson-Berka L. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol. 2006;38(5-6):752-65. doi: 10.1016/j.biocel.2005.08.002.

Chew EY. Dietary Intake of Omega-3 Fatty Acids From Fish and Risk of Diabetic Retinopathy. JAMA. 2017 Jun 6;317(21):2226-2227. doi: 10.1001/jama.2017.1926.

Gustavsson C, Agardh CD, Agardh E. Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol. 2013 Aug;91(5):445-52. doi: 10.1111/j.1755-3768.2012.02430.x.

Barber J, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Feb 28;52(2):1156-63. doi: 10.1167/iovs.10-6293.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan;33 Suppl 1:S62-9. doi: 10.2337/dc10-S062.

Antonetti DA, Klein R, Gardner TW. Diabetic Retinopathy. N Engl J Med. 2012 Mar 29;366(13):1227-39. doi: 10.1056/NEJMra1005073.

Clarke M, Dodson PM. PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):573-86.

Malachkova NV, Kyryliuk ML, Komarovskaya IV. Association between serum resistin level and diabetic retinopathy in obese patients with type 2 diabetes mellitus. J ophthalmol (Ukraine). 2017;(4):9-13. doi: 10.31288/oftalmolzh20174913. (in Russian).

Paranova A, Iliev I, Filipponi M, et al. Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes. J Clin Endocrinol Metab. 2004 Sep;89(9):4371-6. doi: 10.1210/jc.2003-032076.

Kaštelan S, Tomic M, Antunica AG, Rabatic JS. Obesity and Retinopathy in Diabetes. J. Mol. Genet. Med. 2014;S1:020. doi:10.4172/1747-0862.S1-020.

Gavin S. Tan GS, and Tien YinWong T, authors. Diabetic retinopathy and other ocular complications. In: DeFronzo RA, Ferrannini E, Zimmet P, eds. International Textbook of Diabetes Mellitus. 4th ed. Wiley-Blackwell; 2015. p. 881.

Malachkova N, Komarovskaya I, Kyryliuk M. Blood glucose level and insulin resistance in patients with type 2 diabetic mellitus, diabetic retinopathy and obesity. Mìžnarodnij endokrinologìčnij žurnal. 2017;13(3):27-32. doi: 10.22141/2224-0721.13.3.2017.104108.

Pasechnikova NV, Metelicyna IP, Naumenko VA, Beljaev VD. Changes in the level of pro- and anti-inflammatory cytokines in patients with diabetic retinopathy after laser coagulation of the retina. J ophthalmol (Ukraine). 2010;(2):4-7. doi: 10.31288/oftalmolzh2010247.

Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications. 2008 Sep-Oct;22(5):309-16. doi: 10.1016/j.jdiacomp.2007.03.001.

Maberley D, Cui JZ, Matsubara JA. Vitreous leptin levels in retinal disease. Eye (Lond). 2006 Jul;20(7):801-4. doi: 10.1038/sj.eye.6702011.

Abcouwer SF, Antonetti DA. A Role for Systemic Inflammation in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2384. doi: 10.1167/iovs.13-11977.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539-58. doi: 10.1002/sim.1186.

Sierra-Honigmann MR. et al. Biological action of leptin as an angiogenic factor. Science. 1998 Sep 11;281(5383):1683-6. doi: 10.1126/science.281.5383.1683.

Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications. 2003 Nov-Dec;17(6):374-9. doi: 10.1016/s1056-8727(02)00193-9.

Haurigot V, Villacampa P, Ribera A, et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem. 2009 Aug 21;284(34):22961-9. doi: 10.1074/jbc.M109.014787.

Spijkerman MW, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabet Med. 2007 Sep;24(9):969-76. doi: 10.1111/j.1464-5491.2007.02217.x.

Mamtora S, Sandinha T, Carey P, Steel D. Optimizing Medical Management in Patients with Sight Threatening Diabetic Retinopathy. Ophthalmol Ther. 2017 Jun;6(1):105-114. doi: 10.1007/s40123-016-0069-z.

Perk J1, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092.

Serdyuk VN, Ishchenko VA. Morphometric and Biochemical Clusters of Metabolic Syndrome in Type 2 Diabetic Patients at Different Stages of Diabetic Retinopathy. Mìžnarodnij endokrinologìčnij žurnal. 2016;(79):69-74. doi: 10.22141/2224-0721.7.79.2016.86421.

Kyryliuk ML, Serdiuk VM, Pylypenko LYu. Influence of the factors of the progression of diabetics rethinopathy on the concentration of blood fibrinogen at type 2 diabetes as the component of metabolic syndrome. Clinical Endocrinology and Endocrine Surgery. 2017;4(60):64-69. doi.org/10.24026/1818-1384.4(60).2017.118769






Copyright (c) 2020 M.L. Kyryliuk, V.A. Іshchenko

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2020

 

   Seo анализ сайта